What Happened?
Pittsburgh, PA-based NeuBase Therapeutics Appointed Anthony Rossomando as Chief Technology Officer
About the Company
NeuBase is developing ultra precision genetic medicines targeting rare, monogenic diseases, therapeutic candidates for the treatment of myotonic dystrophy type 1 (DM1), Huntington`s disease (HD), and cancer-driving point mutations in KRAS G12V and G12D, which are involved in many tumor types and have historically been “undruggable.” for which there are no approved therapies, as well as more common genetic disorders, including cancers that are resistant to current therapeutic approaches. NeuBase`s pipeline includes
About the Person
Anthony Rossomando is Chief Technology Officer at NeuBase Therapeutics. Previously, Anthony held various senior IT leadership roles in the industry.
Info Source
News
Short Profile